Open Consultations and Surveys

7 results

  • Improvements to the Therapeutic Goods Advertising Code

    The Therapeutic Goods Administration (TGA) within the Department of Health, Disability and Ageing is seeking feedback on options and proposed changes to improve the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021 (the Code). We are reviewing parts of the Code to make sure it: is clear and easy to apply reflects current advertising practices supports safe and appropriate use of therapeutic goods. ... More
    Closes 3 September 2026

  • Proposed changes to Required Advisory Statements for Medicine Labels (RASML)

    The Therapeutic Goods Administration (TGA) is seeking comments from interested parties on proposed changes to the Required Advisory Statements for Medicine Labels (RASML) . RASML sets out advisory statements that are required to be included on the labels of specified OTC and registered complementary medicines. The proposed changes to RASML are: addition of entries for three new substances not currently included in RASML - celecoxib, methenamine and naratriptan ... More
    Closes 4 September 2026

  • Adoption of International Scientific Guidelines in Australia R01-2026

    The Therapeutic Goods Administration (TGA) is seeking feedback on whether or not certain international scientific guidelines should be adopted. Prior to adopting any international scientific guideline, the TGA undertakes an extensive process of internal and external consultation to ensure the international scientific guideline is consistent with prevailing requirements in Australia. The TGA has approximately 370 current adopted international... More
    Closes 11 September 2026

  • Public consultation | Sharing more information about medical devices

    We want your feedback on our proposal to improve sharing information about the safety, quality and performance of medical devices. This will take about 15 minutes to read and complete. The proposed changes intend to provide more information to the public after post-market reviews or investigations of medical devices, particularly where review findings relate to the safety, quality, performance or use of a medical device. These changes align with the intent of An Action Plan... More
    Closes 2 October 2026

  • Additional public consultation on the scheduling of ethylene oxide, propylene oxide and epichlorohydrin

    Proposed scheduling amendments for ethylene oxide, propylene oxide and epichlorohydrin This consultation is in relation to a proposal to amend the current scheduling of ethylene oxide, propylene oxide and epichlorohydrin. All the three substances are listed is the current Poisons Standard as Dangerous Poisons (Schedule 7) without any exception. The applicant proposed that preparations containing less than 0.002% (20 ppm) of ethylene oxide, propylene oxide and... More
    Closes 26 October 2026

  • Form: Confirmation of M2M HL7 SPL testing completion

    This form is for medical device sponsors, manufacturers, or agents. It lets you advise the Therapeutic Goods Administration (TGA) that you confirm that your organisation has completed M2M HL7 SPL testing in accordance with the validation procedure in the M2M HL7 SPL – User Guide – AusUDID and is ready to submit UDI records to the AusUDID Production environment, using HL7 SPL. In particular, the confirmation is designed to reflect that you have undertaken all necessary... More
    Closes 1 January 2100

  • Form: Intent to submit to AusUDID using M2M HL7 SPL

    This form is for medical device sponsors, manufacturers, agents or third party data providers. It lets you advise the Therapeutic Goods Administration (TGA) that you plan to submit data to the Australian Unique Device Identification Database (AusUDID) using the M2M HL7 SPL submission method. Important information: You cannot submit data to the AusUDID using M2M HL7 SPL until this form is completed. For more information on using the M2M... More
    Closes 1 January 2100
7 results. Page 1 of 1